Table 1 Patient characteristics
All patients (n = 282) | Patients without visceral metastasis (n = 220) | Patients with visceral metastasis (n = 62) | |||
|---|---|---|---|---|---|
Curative treatment (n = 151) | BSC (n = 69) | Palliative treatment (n = 30) | BSC (n = 32) | ||
Age | |||||
year, SD ≥ 75 years | 76.5 ± 5.5 | 74.9 ± 4.1 | 80.0 ± 6.6* | 74.2 ± 4.0 | 78.2 ± 5.8 ** |
145 (51.4%) | 62 (41.1%) | 50 (72.5%) * | 12 (40%) | 21 (65.6%) | |
Gender ratio (men/women) | 216/66 (76.6%) | 124/27(82.1%) | 38/31 (55.1%) * | 27/3 (90%) | 27/5 (84.3%) |
WHO performance status ‡ (n = 260) | |||||
0 | 39 (15.0%) | 35 (23.3%) | 0 * | 3 (10.0%) | 1 (3.8%) ** |
1 | 119 (45.8%) | 84 (56.0%) | 11 (20.4%) | 18 (60.0%) | 6 (23.1%) |
2 | 93 (35.8%) | 31 (20.7%) | 38 (70.4%) | 8 (26.7%) | 16 (61.5%) |
3 | 9 (3.5%) | 0 | 5 (9.3%) | 1 (3.3%) | 3 (11.5%) |
Atkinson dysphagia score † (n = 270) | |||||
0 | 31 (11.5%) | 20 (13.2%) | 7 (11.3%) * | 2 (6.9%) | 2 (7.1%) |
1 | 9 (25.5%) | 43 (28.5%) | 6 (9.7%) | 14 (48.3%) | 6 (21.4%) |
2 | 129 (47.8%) | 65 (43.0%) | 39 (62.9%) | 10 (34.5%) | 15 (53.6%) |
3 | 30 (11.1%) | 16 (10.6%) | 7 (11.3%) | 3 (10.3%) | 4 (14.3%) |
4 | 11 (4.1%) | 7 (4.6%) | 3 (4.8%) | 0 | 1 (3.6%) |
Initial weight loss † (n = 219, SD) | 8.4 ± 7.7 | 6.7 ± 6.6 | 12.4 ± 11.3 * | 9.0 ± 5.6 | 13.6 ± 10.0 ** |
Initial weight loss ≥ 10% † | 84 (38.4%) | 40 (28.4%) | 22 (64.7%) * | 11 (40.7%) | 11 (64.7%) |
Initial albumin † (n = 148, g/l, SD) | 35.2 ± 6.9 | 37.7 ± 5.4 | 31.4 ± 8.0 * | 35.2 ± 4.8 | 28.7 ± 6.2 ** |
Creatinine clearance † (n = 172, mL/min, SD) | 67.1 ± 24.5 | 72.4 ± 22.7 | 52.5 ± 23.3 * | 76.1 ± 22.5 | 60.9 ± 26.4 |
Charlson score † (n = 254) | |||||
Mean | 1.4 | 1.3 | 1.7 | 1.2 | 1.6 |
Charlson score at 0 | 78 (30.7%) | 50 (38.5%) | 12 (18.2%) * | 8 (28.6%) | 8 (26.7%) |